Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography-Reference-Cited by-同舟云学术

Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography

Published:2006-07-11 Issue:11 Volume:33 Page:1337-1345
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Perk Lars R.,Visser Otto J.,Stigter-van Walsum M.,Vosjan Maria J. W. D.,Visser Gerard W. M.,Zijlstra Josée M.,Huijgens Peter C.,van Dongen Guus A. M. S.

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-006-0160-0.pdf

Reference18 articles.

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:2453–2463

2. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:3262–3269

3. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786–792

4. Winter JN. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin’s lymphoma. Clin Lymphoma 2004;5 Suppl 1:22–26

5. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896–2902

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New PET Tracers for Lymphoma;PET Clinics;2024-10

2. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model;Journal of Medicinal Chemistry;2024-07-16

3. Good practices for 89Zr radiopharmaceutical production and quality control;EJNMMI Radiopharmacy and Chemistry;2024-05-11

4. ПЭТ-КТ при гематологических злокачественных опухолях: что достигнуто и к чему стремиться;Clinical Oncohematology;2024-04-01

5. Exploring Aqueous Coordination Chemistry of Highly Lewis Acidic Metals with Emerging Isotopes for Nuclear Medicine;Accounts of Chemical Research;2024-03-05